- Home
- OTLK vs PNNT Comparison
OTLK vs PNNT Comparison
Compare OTLK & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | PNNT |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 227.2M |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OTLK | PNNT |
|---|---|---|
| Price | $0.57 | $3.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $5.03 | $4.75 |
| AVG Volume (30 Days) | ★ 3.4M | 424.4K |
| Earning Date | 08-14-2026 | 08-10-2026 |
| Dividend Yield | N/A | ★ 14.54% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,355.64 | $0.19 |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.19 |
| 52 Week High | $2.54 | $6.67 |
Technical Indicators
Market Signals| Indicator | OTLK | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 34.55 |
| Support Level | $0.50 | $3.19 |
| Resistance Level | $0.72 | $3.89 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.06 | 12.41 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.